razoxane has been researched along with Cancer, Second Primary in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caron, HN; Kremer, LC; Raphaël, MF; van Dalen, EC; van den Berg, H | 1 |
| Asselin, BL; Athale, UH; Clavell, L; Cohen, HJ; Cole, PD; Kelly, KM; Larsen, EC; Laverdière, C; Lipshultz, SE; Michon, B; Neuberg, DS; Sallan, SE; Schorin, M; Schwartz, CL; Silverman, LB; Stevenson, KE; Vrooman, LM | 1 |
| Eastmond, DA; Roy, SK | 1 |
| Chauvenet, A; Constine, LS; De Alarcon, PA; Friedman, D; London, WB; Mendenhall, NP; Schwartz, CL; Sposto, R; Tebbi, CK; Villaluna, D | 1 |
| Lipshultz, SE; Lipsitz, SR; Orav, EJ | 1 |
| Asselin, BL; Athale, UH; Barry, EV; Clavell, LA; Cohen, HJ; Dahlberg, SE; Larsen, EC; Lipshultz, SE; Moghrabi, A; Neuberg, DS; Sallan, SE; Samson, Y; Schorin, MA; Silverman, LB; Vrooman, LM | 1 |
| Guo, Y; Xie, X; Xue, Y | 1 |
| Forbes, JF | 1 |
1 review(s) available for razoxane and Cancer, Second Primary
| Article | Year |
|---|---|
Long-term effects of adjuvant chemotherapy in breast cancer.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Female; Heart; Heart Diseases; Hodgkin Disease; Humans; Leukemia; Lymphatic Metastasis; Menopause; Menstruation; Monitoring, Physiologic; Neoplasms, Second Primary; Ovary; Razoxane | 1992 |
2 trial(s) available for razoxane and Cancer, Second Primary
| Article | Year |
|---|---|
Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chelating Agents; Cohort Studies; Enzyme Inhibitors; Female; Follow-Up Studies; Heart Diseases; Hodgkin Disease; Humans; Incidence; Leukemia, Myeloid; Lung Diseases; Male; Myelodysplastic Syndromes; Neoplasm Staging; Neoplasms, Second Primary; Osteosarcoma; Razoxane; Risk Assessment; Risk Factors; Thyroid Neoplasms; Time Factors; Topoisomerase II Inhibitors | 2007 |
Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Hodgkin Disease; Humans; Incidence; Infant; Infant, Newborn; Male; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Razoxane; Survival Rate | 2008 |
5 other study(ies) available for razoxane and Cancer, Second Primary
| Article | Year |
|---|---|
Should anthracyclines and dexrazoxane be used for children with cancer?
Topics: Anthracyclines; Antineoplastic Agents; Child; Heart; Humans; Neoplasms; Neoplasms, Second Primary; Razoxane | 2011 |
The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium.
Topics: Adolescent; Antineoplastic Agents; Cardiotonic Agents; Child; Child, Preschool; Female; Humans; Incidence; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Razoxane; Risk; Time Factors | 2011 |
Bimolane induces multiple types of chromosomal aberrations in human lymphocytes in vitro.
Topics: Antineoplastic Agents; Cells, Cultured; Chromosome Aberrations; Humans; In Situ Hybridization, Fluorescence; Leukemia; Lymphocytes; Male; Micronuclei, Chromosome-Defective; Mutagens; Neoplasms, Second Primary; Nondisjunction, Genetic; Polyploidy; Razoxane | 2011 |
Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without compelling evidence.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hodgkin Disease; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neoplasms, Second Primary; Randomized Controlled Trials as Topic; Razoxane; Risk Assessment; Scientific Misconduct; Sensitivity and Specificity; Survival Rate | 2007 |
Translocation t(7;11)(P15;P15) in a patient with therapy-related acute myeloid leukemia following bimolane and ICRF-154 treatment for psoriasis.
Topics: Acute Disease; Adult; Antineoplastic Agents; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 7; Humans; Karyotyping; Leukemia, Myeloid; Male; Neoplasms, Second Primary; Psoriasis; Razoxane; Translocation, Genetic | 1997 |